/

Empresas

Fo

No verificado

Forlong Biotechnology

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa

21/04/2026

Ferias y Congresos

Análisis de Mercados

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

Forlong Biotechnology to Present Clinical Data from the First-in-human Study for FL115 (IL-15 Superagonist) in US Patients with Advanced Solid Tumors at 2026 ASCO Annual Meeting

Fuente

Forlong Biotechnology

Editor

1.00

0

15/04/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC)

Fuente

Forlong Biotechnology

Editor

1.00

0

17/03/2026

Eventos

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Forlong Biotechology to Present Preclinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, and FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting

Fuente

Forlong Biotechnology

Editor

1.00

0

07/01/2026

Eventos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA

Fuente

Forlong Biotechnology

Editor

1.00

0

30/10/2025

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Eventos

Industria

Forlong Biotechology to Present Clinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, in Late-breaking Session at 40th SITC Annual Meeting

Fuente

Forlong Biotechnology

Editor

1.00

0

30/10/2025

Eventos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC)

Fuente

Forlong Biotechnology

Editor

1.00

0

22/10/2025

Oncología

Salud

Ciencia

Farmacéutica

Biotecnología

Mercado laboral

Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine

Fuente

Forlong Biotechnology

Editor

1.00

0

14/10/2025

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Mercado laboral

Industria

Forlong Biotechnology Receives Milestone Payment as Partner Submits IND for A Protein Therapy using its Proprietary Fbody® Technology

Fuente

Forlong Biotechnology

Editor

1.00

0

Seguidores

0

Compatibilidad

0